WO2006128740A3 - Anti-vascular methods and therapies employing lysyl oxidase inhibitors - Google Patents
Anti-vascular methods and therapies employing lysyl oxidase inhibitors Download PDFInfo
- Publication number
- WO2006128740A3 WO2006128740A3 PCT/EP2006/006692 EP2006006692W WO2006128740A3 WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3 EP 2006006692 W EP2006006692 W EP 2006006692W WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lysyl oxidase
- oxidase inhibitors
- methods
- therapies employing
- vascular
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Abstract
The present invention relates to pharmaceutical compositions and methods of treating angiogenesis related diseases, such as cancer. Specifically, the invention relates to a composition comprising a lysyl oxidase inhibitor alone or in combination with at least one chemotherapeutic agent, as well as use of the composition and/or combination in the treatment of angiogenesis related disease, such as cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68640605P | 2005-06-02 | 2005-06-02 | |
US60/686,406 | 2005-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006128740A2 WO2006128740A2 (en) | 2006-12-07 |
WO2006128740A3 true WO2006128740A3 (en) | 2007-04-12 |
Family
ID=37482014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/006692 WO2006128740A2 (en) | 2005-06-02 | 2006-06-02 | Anti-vascular methods and therapies employing lysyl oxidase inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006128740A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168180B2 (en) | 2002-11-27 | 2012-05-01 | Technion Research & Development Foundation Ltd. | Methods and compositions for modulating angiogenesis |
US8927700B2 (en) | 2009-08-21 | 2015-01-06 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
US9176139B2 (en) | 2007-08-02 | 2015-11-03 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
CN113321743B (en) * | 2021-07-02 | 2022-10-21 | 海南精准医疗科技有限公司 | Chimeric antigen receptor of targeting lysyl oxidase 1 and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011667A2 (en) * | 2000-08-08 | 2002-02-14 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
WO2004037992A2 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Mapk7 as modifier of branching morphogenesis and methods of use |
WO2005038465A2 (en) * | 2003-10-07 | 2005-04-28 | Centelion | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
-
2006
- 2006-06-02 WO PCT/EP2006/006692 patent/WO2006128740A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002011667A2 (en) * | 2000-08-08 | 2002-02-14 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
WO2004037992A2 (en) * | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Mapk7 as modifier of branching morphogenesis and methods of use |
WO2005038465A2 (en) * | 2003-10-07 | 2005-04-28 | Centelion | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
Non-Patent Citations (3)
Title |
---|
GOLDBRUNNER R H ET AL: "MODELS FOR ASSESSMENT OF ANGIOGENESIS IN GLIOMAS", JOURNAL OF NEURO-ONCOLOGY, KLUWER, BOSTON, US, vol. 50, no. 1/2, October 2000 (2000-10-01), pages 53 - 62, XP009035224, ISSN: 0167-594X * |
KIRSCHMANN DAWN A ET AL: "A molecular role for lysyl oxidase in breast cancer invasion", CANCER RESEARCH, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4478 - 4483, XP002414351, ISSN: 0008-5472 * |
KLAUBER N ET AL: "INHIBITION OF ANGIOGENESIS AND BREAST CANCER IN MICE BY THE MICROTUBULE INHIBITORS 2-METHOXYESTRADIOL AND TAXOL", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 1, 1 January 1997 (1997-01-01), pages 81 - 86, XP000982726, ISSN: 0008-5472 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168180B2 (en) | 2002-11-27 | 2012-05-01 | Technion Research & Development Foundation Ltd. | Methods and compositions for modulating angiogenesis |
US9176139B2 (en) | 2007-08-02 | 2015-11-03 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
US9289447B2 (en) | 2009-01-06 | 2016-03-22 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
US8927700B2 (en) | 2009-08-21 | 2015-01-06 | Gilead Biologics, Inc. | Catalytic domains from lysyl oxidase and LOXL2 |
Also Published As
Publication number | Publication date |
---|---|
WO2006128740A2 (en) | 2006-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007064931A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2007103719A3 (en) | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | |
WO2007011962A3 (en) | Treatment of cancer | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
MY191349A (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
WO2006091395A3 (en) | Inhibitors of akt activity | |
WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
WO2006133955A8 (en) | Adamts13-comprising compositions having thrombolytic activity | |
WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2008030883A3 (en) | Treatment of cancer | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
WO2007106537A3 (en) | Aminoquinolones as gsk-3 inhibitors | |
WO2006110638A3 (en) | Inhibitors of akt activity | |
WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
WO2010059004A3 (en) | Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient | |
WO2006020680A3 (en) | Heterocyclic compounds as pharmaceutical agents | |
WO2007002836A3 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
WO2008125116A3 (en) | Upar inhibition | |
WO2006096759A3 (en) | Methods and compositions for treating cancer | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
AP2413A (en) | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease. | |
WO2006108679A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06762498 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06762498 Country of ref document: EP Kind code of ref document: A2 |